Stargardt disease, also referred to as Stargardt macular dystrophy or juvenile macular degeneration, is a genetic eye condition impacting the macula—the part of the retina essential for sharp central vision. Typically emerging in childhood or adolescence, this disorder results in gradual loss of central vision. It stems from mutations in the ABCA4 gene, causing the accumulation of lipofuscin deposits in retinal pigment epithelium cells.
Affected individuals may experience challenges such as blurred vision, difficulty reading, and reduced visual acuity in low light conditions. While currently without a cure, ongoing research strives to deepen our understanding and explore potential therapeutic avenues. Management often involves visual aids like magnifying lenses and adjustments in daily routines to accommodate central vision impairment. Genetic counseling plays a pivotal role in assisting affected individuals and families due to the hereditary nature of Stargardt disease.







Title : Why a paediatric orthoptic oncology service matters
Shenika Tailor, University Hospitals of Leicester NHS Trust, United Kingdom
Title : Stereotactic radiotherapy for wet age-related macular degeneration: year 4 results of a randomised, double-masked, sham-controlled trial
Tim Jackson, King’s College London, United Kingdom